US launch planning · Checked 15 November 2026
Why Korean brands and manufacturers should care
A sunscreen’s feel is part of the product people return for: how it spreads, how it dries and how it sits under makeup. BEMT gives Korean formulators another option for bringing that experience to the US. It can help a US version get closer to the texture and finish customers already love. Whether the original formula can stay unchanged depends on every UV filter and the rest of the product.
Keep the reason people buy it
Protect the feel and finish that built your reputation. A compliant US version can support local retail, reliable replenishment and repeat sales. Starting the formula review early gives you a better chance of reaching those customers before competitors do.
Turn formulation skill into US business
Develop a well-documented US platform that brands can evaluate. Clear ingredient sourcing, testing and drug-manufacturing records make quoting and launch planning easier. Each customer’s final formula still needs its own review.
Some US shoppers already seek out overseas versions because they notice differences in texture and finish. That demand gives brands a useful product brief. A cross-border order containing one or two tubes, however, is not a dependable compliance route. FDA’s personal-importation policy does not give consumers a general right to import unapproved drugs. Build the US business around a lawful product and supply chain. FDA personal-importation policy.
The commercial opportunity is to reduce the gap between the sunscreen customers want and the version they can readily buy in the US. Revenue will still depend on the product, distribution, price and execution. BEMT alone does not deliver a launch.
US launches have started
Bemotrizinol, shortened to BEMT, is a UV filter that helps protect skin from UVA and UVB rays. Its US authorization gives formulators another ingredient to work with.
- Final order issuedFDA OTC000039
- Order takes effectBEMT up to 6%, subject to conditions
- US launch announcedUltra Violette Unblock Screen SPF 50
Ultra Violette announced US availability of Unblock Screen SPF 50 from 31 August 2026. Neutrogena has also announced BEMT-containing Ultra Sheer and Clear Face products. These launches show that the route is being used; they do not establish that another brand’s formula meets the requirements. Ultra Violette announcement; Neutrogena announcement.
Check the whole filter system before changing anything
US sunscreens are regulated as drugs. The OTC monograph is the set of conditions that lets a qualifying product be marketed without a separate approved drug application. FDA’s BEMT order permits a concentration up to 6%, with conditions covering combinations and dosage forms. FDA final order OTC000039.
Ask the laboratory for the full quantitative formula, not just the retail ingredient list. Check every UV filter against the current US conditions. A familiar Korean or EU filter does not automatically qualify for the US monograph route.
Maximum under the US BEMT order
DHHB, ethylhexyl triazone, MBBT and drometrizole trisiloxane are not sunscreen actives listed in M020. A formula using them as UV filters needs a different plan for the US monograph route.
Read M020’s active-ingredient list ↗Review the latest orders as well as the consolidated list. FDA’s September 2026 order removed PABA and trolamine salicylate, with its own implementation provisions. Do not use an old “US-approved filters” spreadsheet as the final check. FDA’s current sunscreen-order summary.
Every filter, level, combination and dosage form fits the US route?
All fitMove to finished-product testing, manufacturing and labeling checks.
BEMT is paired with a filter outside the US monograph?
Change neededDevelop a permitted combination; recheck feel, performance and stability.
The filter system or concentrations need major changes?
Development briefUse the original feel as a target and plan a new formula and test schedule.
Preserve the sensory brief while the laboratory develops the formula: spreadability, white cast, dry-down, shine, pilling and makeup compatibility. Compare prototypes with the original and agree which differences are acceptable before committing to packaging or launch claims.
Confirm your right to use the BEMT supply
The order grants DSM Nutritional Products LLC and its qualifying licensees, assignees or successors an 18-month exclusivity period under the statutory terms. This affects who may market products using the change. Ask for written confirmation that your supplier and planned product are covered. A purchase invoice alone is not that confirmation. Order, section V; 21 USC 355h(b)(5)(C).
Use the order’s effective-date and lawful-marketing terms when reviewing the period. We have not used a retailer’s launch announcement to calculate an expiry date. Confirm the applicable authorization and timing before switching suppliers or making a launch commitment.
Test the product you will actually sell
A change in filters, their levels or the formula can change protection and wear. Agree the test plan with the laboratory for the final US formula and packaging. Do not carry over a Korean SPF result or a prototype report without checking whether it supports the final product and the US method.
Support the claimed number using the applicable US test procedure.
For this claim, demonstrate the required critical wavelength of at least 370 nm.
Use a supported 40- or 80-minute claim only when the product passes the relevant test.
FDA’s sunscreen labeling and effectiveness-testing guide explains these methods. Also establish suitable stability, microbiological quality and packaging-compatibility evidence with the manufacturer. SPF testing alone does not establish shelf life or production quality.
Give the brand and factory a shared launch checklist
- Freeze the US product brief. Choose the formula version, claims, pack sizes and intended sales channels.
- Clear the ingredient and supply review. Record each filter’s level and function, the permitted combination and BEMT authorization.
- Finish the evidence. Connect testing, stability and batch specifications to the exact formula and packaging.
- Confirm the factory’s drug requirements. Check establishment registration, the foreign establishment’s US-agent arrangement, applicable drug GMP and OMUFA fee obligations.
- Complete the US pack and listing. Review Drug Facts, warnings, directions and other required labeling; assign responsibility for drug listing and its updates.
- Prepare for life after launch. Assign complaint handling, serious-adverse-event reporting, change control and recall responsibilities before the first shipment.
Registration and drug listing are handled through FDA’s electronic drug registration and listing system. FDA registration, an NDC number or a listing is not product approval or factory certification. Ask what was registered, by whom and for which activity. FDA’s explanation of approval versus registration.
For facility fees, use the current OMUFA schedule and confirm whether the specific site is fee-liable. A fee quoted for an earlier fiscal year may no longer apply. Put the actual testing, supply and manufacturing lead times into your launch calendar rather than promising a fixed number of months.
Start with one formula, then build the launch plan
Send your manufacturer the sunscreen you want to preserve and a short description of what customers love about it. Ask for a side-by-side US formula assessment, the changes needed and the evidence still missing. That gives both teams a concrete starting point for costs, prototypes and timing.
Bring your sunscreen and your US brief
Noedal can help organize the formula, labeling and market-entry review with your team. Start with the ingredient levels, current packaging and available test reports.
Plan your US reviewThis is a planning guide, not a product approval. Regulatory status was checked on the date above. Launch decisions need the current requirements and evidence for the finished product.


